Abbott India Ltd.

ABBOTINDIA

₹28584.6

2.04% (572.1)

Market Cap

₹60,854 Cr.

P/E

50.66

About

Abbott India Limited, a subsidiary of Abbott Laboratories, is a leading pharmaceutical company in India. It offers a wide range of trusted medicines in various therapeutic categories. With expertise i… Read more

Abbott India Limited, a subsidiary of Abbott Laboratories, is a leading pharmaceutical company… Read more

Low

22000

52W Range

High

29639

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

32.48%

3yr Average

30.19%

5yr Average

28.3%

Net Profit Margin

Latest

20.54%

3yr Average

18.18%

5yr Average

17.01%

ROCE

Latest

42.51%

3yr Average

39.26%

5yr Average

36.47%

Debt to Equity

Latest

3yr Average

0.0

5yr Average

0.0

Market Share

0 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.67 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.02 %

(as of Nov 20)

Historic

Antineo Plastic - Market Share

1.96 %

(as of May 19)

Historic

Blood Related - Market Share

0.32 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

32.40 %

(as of Mar 19)

Source/Historic

Creon - Market Share

0.61 %

(as of Nov 21)

Historic

Dermatology - Market Share

13.30 %

(as of Mar 19)

Source/Historic

Digene - Market Share

13.90 %

(as of Mar 19)

Source/Historic

Duphalac - Market Share

25.50 %

(as of Mar 19)

Source/Historic

Duphaston - Market Share

13.36 %

(as of Nov 21)

Historic

Endocrinology - Market Share

7.85 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

5.35 %

(as of Nov 21)

Historic

Gynecology - Market Share

63.40 %

(as of Mar 19)

Source/Historic

Influvac - Market Share

4.90 %

(as of Nov 21)

Historic

Neurological - Market Share

0.44 %

(as of Nov 21)

Historic

Pain - Market Share

6.20 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

0.08 %

(as of Nov 21)

Historic

Respiratory - Market Share

0 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.02 %

(as of Apr 20)

Historic

Stomatological - Market Share

51.60 %

(as of Mar 19)

Source/Historic

Thyronorm - Market Share

16.70 %

(as of Mar 19)

Source/Historic

Udiliv - Market Share

1.81 %

(as of Jul 22)

Historic

Vaccines - Market Share

30.80 %

(as of Mar 19)

Source/Historic

Vertin - Market Share

4.51 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Acute vs Chronic

Dosage Form Break-Up

Brand Wise Break-Up

Operational Metrics

Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Brufen

Cremaffin Plus

Digene

Duphalac

Duphaston

Thyronorm

Zolfresh

Suppliers

Aarti Drugs Ltd.
TCI Express Ltd.
Suven Life Sciences Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
TCPL Packaging Ltd.
Snowman Logistics Ltd.
Prabhat Dairy Ltd.
Empire Industries Ltd.
Kilitch Drugs (India) Ltd.
Take Solutions Ltd.
Arshiya Ltd.

Showing 5 of 11

FAQs on Abbott India Ltd. Business

What does Abbott India do?

Abbott India Limited, a subsidiary of Abbott Laboratories, is a leading pharmaceutical company in India offering a wide range of high-quality medicines in various therapeutic categories with a focus on product development and clinical support.

Who are the competitors of Abbott India?

Abbott India major competitors are Alkem Laboratories, Glaxosmithkline Phar, Glenmark Pharma, Aurobindo Pharma, Lupin, Mankind Pharma, Gland Pharma.
Market Cap of Abbott India is ₹60,854 Crs.
While the median market cap of its peers are ₹63,319 Crs.

Is Abbott India financially stable compared to its peers?

Abbott India seems to be financially stable compared to its peers.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate peers.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Jun Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Jun Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Jun Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun Mar	Mar Jun Sep Dec	Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec